Invivyd, Inc.
IVVDHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframePart of the healthcare sector, Invivyd, Inc. (IVVD) is listed under Biotechnology. The company carries a $359.4M market cap, placing it firmly in the small-cap category. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Market Cap
$359.4M
Beta
0.71
P/E (TTM)
—
P/E (Fwd)
-2.10
EPS (TTM)
$-0.29
EPS (Fwd)
$-0.58
ROE
-60.3%
ROA
-29.6%
Cash
$184.2M
Total Debt
$8.6M
Free CF
-$50.1M
52W Change
26.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $184.2M in cash comfortably exceeding the $8.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$50.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -60.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IVVD.